Reliable Quality

Affordable Innovation

Research Progress

Up to date, in addition to two products launched commercially and two products under NDA review, Henlius has conducted over 20 clinical studies for 10 products and 8 combination therapies worldwide. 汉利康® (HLX01, rituximab injection), the first product of Henlius, has been approved by the NMPA as China’s first biosimilar in February 2019. The second product 汉曲优® (HLX02, trastuzumab injection, Zercepac® in the EU) was launched both in China and Europe in 2020, becoming the first Chinese mAb biosimilar entering both the EU and China market. It will bring more treatment options to patients with HER2 positive breast and gastric cancer worldwide.HLX03 (adalimumab injection) and HLX04 (bevacizumab injection) were accepted for NDA review with HLX03 to be potentially launched in 2020.

Products in R&D
Target
Generic Name
Study Phase
Potential Indication
Study Phase
Product Pipeline

With the efficient and innovative in-house capabilities, Henlius has developed a diversified and advanced drug pipeline with a focus in the fields of oncology, autoimmune diseases etc.